Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-05-01
|
Series: | Communications Medicine |
Online Access: | https://doi.org/10.1038/s43856-023-00290-0 |